Dai Zeqi, Liao Xing, Wieland L Susan, Hu Jing, Wang Yongyan, Kim Tae-Hun, Liu Jian-Ping, Zhan Siyan, Robinson Nicola
Center for Evidence Based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China; China Center for Evidence Based Traditional Chinese Medicine, Beijing 100700, China.
Center for Evidence Based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Phytomedicine. 2022 Apr;98:153921. doi: 10.1016/j.phymed.2021.153921. Epub 2022 Jan 10.
Systematic reviews on traditional Chinese medicine (TCM) are constantly increasing. However, if these reviews are to be of practical value, the evidence needs to be relevant, valid, and adequately reported. Cochrane Systematic Reviews (CSRs) are considered as high-quality systematic reviews that can inform health care decision making. Our aim was to provide an overview of the scope, findings, quality and impact of CSRs on the benefits and harms associated with TCM interventions for the treatment and prevention of disease to provide new information for clinical practice and future research.
The Cochrane Database of Systematic Reviews was searched up to May 2021, and descriptive characteristics were extracted. The correspondence between the questions asked in the CSRs and the available evidence, conclusions and certainty of findings (according to GRADE assessment), methodological quality (AMSTAR 2), and impact (Altmetric Attention Score [AAS], total citations by guideline, and total citations in Web of Science [WoS]) of CSRs were extracted. Tabular and graphical summaries of these descriptive characteristics were constructed.
Of 104 CSRs on TCM identified, 70 diseases belonged to 16 disease systems and contained 1642 primary studies with 157,943 participants. Interventions included Chinese herbal medicine (n = 70), acupuncture (n = 28), TCM exercises (n = 4), and moxibustion (n = 2). Among 1642 primary studies, 662 studies included an intervention group treated with at least one TCM therapy and 980 studies included a combination of therapies. Promising outcomes from the 104 CSRs were divided into endpoint outcomes (34 diseases), doctor- or patient-reported outcomes (27 diseases), and surrogate outcomes (37 diseases). Despite the presence of promising outcomes, only 5/104 CSRs drew overall positive conclusions, 42 CSRs concluded the evidence was insufficient, and 54 failed to draw firm conclusions. GRADE assessments were reported in 41.3% of the CSRs, and the ratings were mostly low or very low. Comparing the questions asked and results obtained, there was frequently a lack of information about specific outcomes. Only 16 CSRs obtained results for all outcomes listed in the methods section. According to AMSTAR 2, 51 CSRs (49.0%) were of low quality. The total number of citations in the WoS was 2135 (mean ± SD: 20.8 ± 21.2), and 38.5% of the CSRs had been cited in guidelines 95 times.
Although TCM is commonly used, evidence of its effectiveness remains largely inconclusive. Rigorous high-quality trials are needed to support the performance of high-quality reviews and to increase the evidence base. It is critical to emphasize quality over quantity in future TCM research.
关于传统中医(TCM)的系统评价不断增加。然而,要使这些评价具有实际价值,证据需要相关、有效且得到充分报告。Cochrane系统评价(CSRs)被视为高质量的系统评价,可为医疗保健决策提供依据。我们的目的是概述CSRs关于中医干预治疗和预防疾病的益处和危害的范围、结果、质量和影响,为临床实践和未来研究提供新信息。
检索截至2021年5月的Cochrane系统评价数据库,并提取描述性特征。提取CSRs中提出的问题与现有证据、结论和研究结果的确定性(根据GRADE评估)、方法学质量(AMSTAR 2)以及CSRs的影响(Altmetric关注度得分[AAS]、指南总引用次数和科学引文索引[WoS]中的总引用次数)之间的对应关系。构建这些描述性特征的表格和图形摘要。
在确定的104篇关于中医的CSRs中,70种疾病属于16个疾病系统,包含1642项原始研究,涉及157,943名参与者。干预措施包括中药(n = 70)、针灸(n = 28)、中医功法(n = 4)和艾灸(n = 2)。在1642项原始研究中,662项研究包括至少一种中医治疗的干预组,98项研究包括联合治疗。104篇CSRs中显示有前景的结果分为终点结局(34种疾病)、医生或患者报告的结局(27种疾病)和替代结局(37种疾病)。尽管存在有前景的结果,但只有5/104篇CSRs得出总体阳性结论,42篇CSRs得出证据不足的结论,54篇未能得出明确结论。41.3%的CSRs报告了GRADE评估,评级大多为低或极低。比较提出的问题和获得的结果,经常缺乏关于特定结局的信息。只有16篇CSRs获得了方法部分列出的所有结局的结果。根据AMSTAR 2,51篇CSRs(49.0%)质量较低。WoS中的总引用次数为2135次(均值±标准差:20.8 ± 21.2),38.5%的CSRs在指南中被引用95次。
尽管中医被广泛使用,但其有效性的证据在很大程度上仍不明确。需要严格的高质量试验来支持高质量评价的开展并增加证据基础。在未来的中医研究中,强调质量而非数量至关重要。